| Q28270011 | 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine |
| Q34565712 | 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings |
| Q28268394 | 5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine |
| Q33940236 | A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties |
| Q45071429 | A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. |
| Q35105559 | Acute Psychological and Neurophysiological Effects of MDMA in Humans |
| Q46016057 | Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. |
| Q34749393 | Arylethylamine psychotropic recreational drugs: a chemical perspective. |
| Q51538484 | Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. |
| Q37622283 | Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. |
| Q24670108 | Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines |
| Q33833054 | Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats |
| Q52206760 | Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists. |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q35965775 | Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats |
| Q53087323 | Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine. |
| Q37196303 | Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations |
| Q52237736 | Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination |
| Q44830693 | Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. |
| Q48172201 | Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat. |
| Q41276719 | Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG). |
| Q39292988 | Hallucinogens in Drug Discrimination |
| Q34461106 | Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential |
| Q42395888 | Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents |
| Q41278263 | MDMA produces stimulant-like conditioned locomotor activity |
| Q36330296 | Methamphetamine-induced neurotoxicity: structure activity relationships |
| Q48686930 | Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues |
| Q43095101 | N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats |
| Q24619949 | Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) |
| Q48863229 | Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus |
| Q56638625 | Psychedelika |
| Q48655798 | Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine |
| Q34565898 | Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? |
| Q24629918 | Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys |
| Q52196710 | Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. |
| Q34607458 | Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue |
| Q52243743 | Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? |
| Q31454903 | Synthesis of 2,3- and 3,4-methylenedioxyphenylalkylamines and their regioisomeric differentiation by mass spectral analysis using GC-MS-MS. |
| Q30341737 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). |
| Q51597223 | The discriminative stimulus effects of methamphetamine in pigeons. |
| Q50921579 | The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. |
| Q35146115 | The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). |
| Q42762761 | The rise (and fall?) of drug discrimination research |
| Q73705416 | Time course analysis of the discriminative stimulus effects of the optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) |
| Q93196767 | Using Ca2+-channel biosensors to profile amphetamines and cathinones at monoamine transporters: electro-engineering cells to detect potential new psychoactive substances |
| Q54297002 | Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. |